BioRestorative to Present New Data at ISCT 2026 Annual Meeting
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 30 2026
0mins
Should l Buy BRTX?
Source: Newsfilter
- Clinical Trial Progress: BioRestorative will present safety and blinded efficacy data from its Phase 2 clinical trial for chronic lumbar disc disease at the 2026 ISCT Annual Meeting, which is expected to bolster investor confidence in its therapeutic solutions.
- Technology Innovation Showcase: The company will introduce preclinical data on its MSC exosome platform, indicating potential applications in therapeutic and cosmetic fields, which may open new avenues for future product development.
- FDA Approval Milestone: BRTX-100 has received Investigational New Drug (IND) clearance from the FDA for treating chronic cervical discogenic pain, marking a significant milestone in the company's clinical development and potentially accelerating market entry.
- Broad Market Potential: BioRestorative's biopharmaceutical platform combines cell therapies with bio-cosmetic products, which is expected to attract significant market demand for anti-aging and metabolic disease solutions, further enhancing the company's competitive position.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy BRTX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on BRTX
Wall Street analysts forecast BRTX stock price to rise
1 Analyst Rating
1 Buy
0 Hold
0 Sell
Moderate Buy
Current: 0.225
Low
8.00
Averages
8.00
High
8.00
Current: 0.225
Low
8.00
Averages
8.00
High
8.00
About BRTX
BioRestorative Therapies, Inc. is engaged in developing therapeutic products using cell and tissue protocols, primarily involving adult stem cells. The Company has two core programs that relate to the treatment of disc/spine disease and metabolic disorders. Its lead cell therapy candidate, BRTX-100, is a product formulated from autologous (or a person's own) cultured mesenchymal stem cells collected from the patient's bone marrow. It has commenced a Phase II clinical trial using BRTX-100 to treat chronic lower back pain arising from degenerative disc disease. The Company is engaged in developing a cell-based therapy candidate, ThermoStem Program, which targets obesity and metabolic disorders using brown adipose (fat) derived stem cells to generate brown adipose tissue (BAT). It has also licensed an investigational curved needle device designed to deliver cells and/or other therapeutic products or material to the spine and discs. It also operates a commercial biocosmeceutical platform.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
BioRestorative Reports Positive Phase 2 Trial Results for BRTX-100
- Clinical Trial Update: BioRestorative presented updated data on BRTX-100 at ISCT 2026, revealing that 52% of evaluable patients achieved at least 50% improvement in both VAS and ODI measures at 52 weeks, indicating the therapy's potential for chronic lumbar disc disease treatment.
- Increased Patient Evaluation: The number of patients evaluated at 52 weeks rose from 12 to 25, reflecting enhanced participation in the clinical trial, while no adverse events related to dose-limiting toxicities were observed, further validating the safety profile of BRTX-100.
- Sustained Efficacy: Across multiple validated measures including VAS, ODI, RMDQ, and FRI, 56% of patients reported at least 50% improvement at 52 weeks, with average improvement rates reaching 73.8% at 104 weeks, demonstrating the therapy's sustained and stable efficacy.
- FDA Fast Track Designation: BRTX-100 has received Fast Track designation from the FDA, aimed at expediting development and review, with BioRestorative planning to submit a Phase 3 IND application later in 2026 to further advance the clinical progress of this therapy.
See More
BioRestorative to Present New Data at ISCT 2026 Annual Meeting
- Clinical Trial Progress: BioRestorative will present safety and blinded efficacy data from its Phase 2 clinical trial for chronic lumbar disc disease at the 2026 ISCT Annual Meeting, which is expected to bolster investor confidence in its therapeutic solutions.
- Technology Innovation Showcase: The company will introduce preclinical data on its MSC exosome platform, indicating potential applications in therapeutic and cosmetic fields, which may open new avenues for future product development.
- FDA Approval Milestone: BRTX-100 has received Investigational New Drug (IND) clearance from the FDA for treating chronic cervical discogenic pain, marking a significant milestone in the company's clinical development and potentially accelerating market entry.
- Broad Market Potential: BioRestorative's biopharmaceutical platform combines cell therapies with bio-cosmetic products, which is expected to attract significant market demand for anti-aging and metabolic disease solutions, further enhancing the company's competitive position.
See More
BioRestorative Partners with Dermatologist to Enhance BioCosmeceutical Platform
- Strategic Partnership: BioRestorative Therapies, Inc. (BRTX) has formed a strategic partnership with renowned dermatologist Dr. David J. Goldberg to accelerate clinical validation and market adoption of its regenerative BioCosmeceutical platform, which is expected to significantly enhance brand influence and market penetration.
- Clinical Study Leadership: Dr. Goldberg will lead a prospective, controlled human clinical study evaluating BioRestorative's biologics, enriched with exosomes, growth factors, cytokines, and peptides, aimed at generating comparative outcome data on skin improvements relative to current aesthetic benchmarks, thereby driving both scientific and commercial advancement.
- Market Expansion Potential: With Dr. Goldberg's involvement, BioRestorative anticipates expanding access to influential physician networks, enhancing brand positioning, and supporting evidence-based adoption across clinics and consumer markets, further driving its penetration in professional and consumer sectors.
- Infrastructure Development: This partnership represents the third pillar of BioRestorative's broader strategy for its BioCosmeceutical business, combining cleanroom manufacturing capabilities and commercial execution with 203 Creates, aimed at establishing the necessary infrastructure to compete in the rapidly growing regenerative aesthetics market.
See More
Zevra Therapeutics Reports Strong Q4 Earnings, Shares Surge
- Earnings Beat: Zevra Therapeutics reported Q4 earnings of $0.19 per share, significantly surpassing the analyst consensus of $0.05, indicating a notable improvement in profitability and boosting investor confidence.
- Sales Growth: The company achieved quarterly sales of $34.125 million, exceeding the analyst estimate of $28.051 million, reflecting strong product demand and solid market performance, which may drive future growth potential.
- Stock Surge: Following the earnings report, Zevra Therapeutics shares jumped 17.2% to $10.70 in pre-market trading, indicating a positive market reaction to the company's performance and potentially attracting more investor interest.
- Optimistic Market Outlook: This earnings beat not only enhances the company's short-term stock price but may also lay a foundation for long-term development, strengthening market confidence in its future growth prospects.
See More
BioRestorative Secures Patent Protection in Australia
- Patent Protection Enhanced: BioRestorative has received approval from IP Australia for its patent application covering the method of creating three-dimensional brown adipose-derived stem cell aggregates, further solidifying its market position in obesity and metabolic disease treatments.
- Technological Advantages Revealed: This patent provides the broadest protection for BioRestorative's ThermoStem® technology, aimed at developing safer and more effective cell-based therapies compared to GLP-1 drugs, showcasing the company's competitive potential in the rapidly growing therapeutic market.
- Global Strategic Expansion: CEO Lance Alstodt emphasized that securing this patent is a significant step in expanding the company's global IP portfolio, aimed at enhancing its leadership in stem cell therapies through continuous technological innovation and market protection.
- Clinical Trial Progress: BioRestorative is conducting a Phase 2 clinical trial for BRTX-100 targeting chronic lower back pain, and with the newly acquired patent, it is expected to accelerate its commercialization process in the regenerative medicine field.
See More
BioRestorative Closes Public Offering of 14.29 Million Shares
- Successful Public Offering: BioRestorative Therapies has closed its public offering of 14,285,715 shares at a price of $0.35 per share, raising approximately $5 million in gross proceeds, which reflects the company's funding needs and market confidence in the regenerative medicine sector.
- Clear Use of Proceeds: The net proceeds will be allocated to clinical trials for BRTX-100, pre-clinical research for the ThermoStem Program, and the development of its commercial biocosmeceuticals platform, indicating a strategic focus on product diversification and technological innovation.
- Regulatory Compliance: The registration statement for this offering was declared effective by the SEC on February 11, 2026, ensuring transparency and legality, which helps to enhance investor confidence in the company's operations.
- Broad Market Prospects: BioRestorative's lead product BRTX-100 is currently in Phase 2 clinical trials for chronic lower back pain, and with FDA IND clearance, it signals potential market opportunities and future growth in the regenerative medicine field.
See More
BioRestorative Reports Positive Phase 2 Trial Results for BRTX-100
- Clinical Trial Update: BioRestorative presented updated data on BRTX-100 at ISCT 2026, revealing that 52% of evaluable patients achieved at least 50% improvement in both VAS and ODI measures at 52 weeks, indicating the therapy's potential for chronic lumbar disc disease treatment.
- Increased Patient Evaluation: The number of patients evaluated at 52 weeks rose from 12 to 25, reflecting enhanced participation in the clinical trial, while no adverse events related to dose-limiting toxicities were observed, further validating the safety profile of BRTX-100.
- Sustained Efficacy: Across multiple validated measures including VAS, ODI, RMDQ, and FRI, 56% of patients reported at least 50% improvement at 52 weeks, with average improvement rates reaching 73.8% at 104 weeks, demonstrating the therapy's sustained and stable efficacy.
- FDA Fast Track Designation: BRTX-100 has received Fast Track designation from the FDA, aimed at expediting development and review, with BioRestorative planning to submit a Phase 3 IND application later in 2026 to further advance the clinical progress of this therapy.
See More
BioRestorative to Present New Data at ISCT 2026 Annual Meeting
- Clinical Trial Progress: BioRestorative will present safety and blinded efficacy data from its Phase 2 clinical trial for chronic lumbar disc disease at the 2026 ISCT Annual Meeting, which is expected to bolster investor confidence in its therapeutic solutions.
- Technology Innovation Showcase: The company will introduce preclinical data on its MSC exosome platform, indicating potential applications in therapeutic and cosmetic fields, which may open new avenues for future product development.
- FDA Approval Milestone: BRTX-100 has received Investigational New Drug (IND) clearance from the FDA for treating chronic cervical discogenic pain, marking a significant milestone in the company's clinical development and potentially accelerating market entry.
- Broad Market Potential: BioRestorative's biopharmaceutical platform combines cell therapies with bio-cosmetic products, which is expected to attract significant market demand for anti-aging and metabolic disease solutions, further enhancing the company's competitive position.
See More
BioRestorative Partners with Dermatologist to Enhance BioCosmeceutical Platform
- Strategic Partnership: BioRestorative Therapies, Inc. (BRTX) has formed a strategic partnership with renowned dermatologist Dr. David J. Goldberg to accelerate clinical validation and market adoption of its regenerative BioCosmeceutical platform, which is expected to significantly enhance brand influence and market penetration.
- Clinical Study Leadership: Dr. Goldberg will lead a prospective, controlled human clinical study evaluating BioRestorative's biologics, enriched with exosomes, growth factors, cytokines, and peptides, aimed at generating comparative outcome data on skin improvements relative to current aesthetic benchmarks, thereby driving both scientific and commercial advancement.
- Market Expansion Potential: With Dr. Goldberg's involvement, BioRestorative anticipates expanding access to influential physician networks, enhancing brand positioning, and supporting evidence-based adoption across clinics and consumer markets, further driving its penetration in professional and consumer sectors.
- Infrastructure Development: This partnership represents the third pillar of BioRestorative's broader strategy for its BioCosmeceutical business, combining cleanroom manufacturing capabilities and commercial execution with 203 Creates, aimed at establishing the necessary infrastructure to compete in the rapidly growing regenerative aesthetics market.
See More
Zevra Therapeutics Reports Strong Q4 Earnings, Shares Surge
- Earnings Beat: Zevra Therapeutics reported Q4 earnings of $0.19 per share, significantly surpassing the analyst consensus of $0.05, indicating a notable improvement in profitability and boosting investor confidence.
- Sales Growth: The company achieved quarterly sales of $34.125 million, exceeding the analyst estimate of $28.051 million, reflecting strong product demand and solid market performance, which may drive future growth potential.
- Stock Surge: Following the earnings report, Zevra Therapeutics shares jumped 17.2% to $10.70 in pre-market trading, indicating a positive market reaction to the company's performance and potentially attracting more investor interest.
- Optimistic Market Outlook: This earnings beat not only enhances the company's short-term stock price but may also lay a foundation for long-term development, strengthening market confidence in its future growth prospects.
See More
BioRestorative Secures Patent Protection in Australia
- Patent Protection Enhanced: BioRestorative has received approval from IP Australia for its patent application covering the method of creating three-dimensional brown adipose-derived stem cell aggregates, further solidifying its market position in obesity and metabolic disease treatments.
- Technological Advantages Revealed: This patent provides the broadest protection for BioRestorative's ThermoStem® technology, aimed at developing safer and more effective cell-based therapies compared to GLP-1 drugs, showcasing the company's competitive potential in the rapidly growing therapeutic market.
- Global Strategic Expansion: CEO Lance Alstodt emphasized that securing this patent is a significant step in expanding the company's global IP portfolio, aimed at enhancing its leadership in stem cell therapies through continuous technological innovation and market protection.
- Clinical Trial Progress: BioRestorative is conducting a Phase 2 clinical trial for BRTX-100 targeting chronic lower back pain, and with the newly acquired patent, it is expected to accelerate its commercialization process in the regenerative medicine field.
See More
BioRestorative Closes Public Offering of 14.29 Million Shares
- Successful Public Offering: BioRestorative Therapies has closed its public offering of 14,285,715 shares at a price of $0.35 per share, raising approximately $5 million in gross proceeds, which reflects the company's funding needs and market confidence in the regenerative medicine sector.
- Clear Use of Proceeds: The net proceeds will be allocated to clinical trials for BRTX-100, pre-clinical research for the ThermoStem Program, and the development of its commercial biocosmeceuticals platform, indicating a strategic focus on product diversification and technological innovation.
- Regulatory Compliance: The registration statement for this offering was declared effective by the SEC on February 11, 2026, ensuring transparency and legality, which helps to enhance investor confidence in the company's operations.
- Broad Market Prospects: BioRestorative's lead product BRTX-100 is currently in Phase 2 clinical trials for chronic lower back pain, and with FDA IND clearance, it signals potential market opportunities and future growth in the regenerative medicine field.
See More
